Navigation Links
SARcode Bioscience Completes $44 Million Series B Financing
Date:7/18/2011

BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing.  The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

(Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO)

"We believe that SARcode is uniquely positioned to make significant breakthroughs in the treatment of dry eye that could improve therapeutic options for millions of patients," commented Garheng Kong, General Partner of Sofinnova Ventures.  "SARcode's proprietary compound has demonstrated the ability to alleviate both the signs and symptoms of dry eye by directly targeting the inflammatory origin of this debilitating disease," Kong added.  "We have been impressed by the broad ophthalmic product development and marketing experience of the SARcode executive team and look forward to working with them and the investor syndicate as the company's lead dry eye program moves into Phase 3 clinical trials," said Martin Vogelbaum, Partner at Rho Ventures.

Proceeds from the Series B financing will largely support further clinical development of SAR 1118, SARcode's lead compound for the treatment of dry eye syndrome.  SAR 1118 is a first-in-class, topical small-molecule integrin antagonist that inhibits T-cell mediated inflammation, a key component of dry eye.  In a Phase 2 randomized, placebo-controlled trial of 230 subjects with dry eye disease, SAR 1118 demonstrated an improvement in corneal staining at 12 weeks and an increase in tear production as early as 2 weeks.  In addition, subjects receiving SAR 1118 reported dose-dependent improvements in visual-related function at 12 weeks, which included the ability to read, drive at night, use a computer and watch television.  SAR 1118 was
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
3. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Calif. , May 20, 2013 A ... for use both in space and on Earth was ... The technology assures high quality, secure ... and low-power ultrasound units, like those used in hospitals ... already the diagnostic imaging solution of choice for human ...
(Date:5/20/2013)... 20, 2013 Hyland Software expands upon ... creating the Multi-Disciplinary Clinical Leadership Team. Led by ... experts with diverse healthcare experience, the team will ... create new software solutions that will enhance the ... patients and staff. Healthcare organizations use ...
(Date:5/20/2013)...  Neuralstem, Inc. (NYSE MKT: CUR) today reported that ... investigator, presented updated Phase I data from its spinal ... treatment of amyotrophic lateral sclerosis (ALS or ... special medical symposium in Bucharest, Romania ... Advances in Stem Cell Therapy," Dr. Feldman outlined the ...
Breaking Medicine Technology:Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... N.J. and URBANA, Ill., Dec. 6, 2011  Bayer ... into an outcomes-based contract for people with relapsing-remitting ... beta-1b) to reduce the frequency of clinical exacerbations.  ... for Bayer HealthCare in the U.S. and is ...
... SPRING, Md., Dec. 6, 2011 The U.S. Food and ... issued seven Warning Letters to companies marketing over-the counter ... weight loss. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... hormone produced by the human placenta and found in ...
Cached Medicine Technology:Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 2Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 3Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 4FDA, FTC Act to Remove "Homeopathic" HCG Weight Loss Products from the Market 2FDA, FTC Act to Remove "Homeopathic" HCG Weight Loss Products from the Market 3
(Date:5/20/2013)... 2013 Heritage Woods of Gurnee ... County, Illinois, is hosting Breakfast and Bingo at 8:30 ... is located at 3775 Grand Ave. in Gurnee, Illinois, ... Medicaid, who need some help to maintain their independence. ... games of bingo," says Tammy Temaner-Rosas, Director of Marketing ...
(Date:5/20/2013)... Los Angeles, California (PRWEB) May 20, 2013 ... surgery done, it's not always to become ... to a May 7, 2013 ABC News report ... About Family”abcnews.go.com/Politics/OTUS/chris-christie-secretly-lap-band-weight-loss-surgery/story?id=19124435#.UZrR0bWUTDk) made it clear that the surgery ... a presidential candidate or gain celebrity status as ...
(Date:5/20/2013)... May 20, 2013 In order to prepare ... and wellness team from DrSmartphoneMD launched an article series to ... , The series launched with the precautions that ... of the DrSmartphoneMD program are not one of the 3.5 ... that more than 90% of all skin cancer cases are ...
(Date:5/20/2013)... People are so busy these days, running ... through the roof and are contributing to a number of ... mean the difference between life and death. Speakers at the ... May will share valuable, practical tools people can use to ... around them for social good. , Organised by V ...
(Date:5/20/2013)... 20, 2013 The Environmental ... feature dozens of continuing education credit opportunities for ... Institute of Architects Continuing Education System (AIA/CES), the ... the Interior Design Continuing Education Council (IDCEC). ... 1, 2013 at the Omni Providence Hotel in ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Combat Skin Cancer In Summer Months 2Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2
... Re-elect Directors, Ratify E&Y and Approve Charter Amendment; ... Board Re-appoints Leadership, ... the "Company") said today that its Board of Directors declared,a regular ... 2008 to stockholders of record on June 4, 2008. The dividend ...
... Calif., May 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... S.,Williams has rejoined the company in a ... a wholly owned subsidiary of Alexza. Mr.,Williams ... Alexza,subsidiary in Singapore and establishing potential joint ...
... VALLEY FORGE, Pa., May 19 The St. Jude ... first drywall ever manufactured at the,new CertainTeed Gypsum Plant ... for St. Jude Children,s Research Hospital, CertainTeed is,donating gypsum ... the,house., (Logo: http://www.newscom.com/cgi-bin/prnh/20070102/CLTU053LOGO ), The ...
... Provides Development Expertise for Partners ... Developing on the Google Health Platform, PORTLAND, Ore., May ... and development company, announced,collaboration today with Google as a development ... to the public at an,event at Google,s headquarters today; the ...
... Program seeks to advance knowledge of mysterious conditions , , ... program designed to help patients with mysterious health conditions ... U.S. National Institutes of Health. , The Undiagnosed Diseases ... to the NIH Clinical Center by doctors across the ...
... of Nebraska Medical Center-led pilot study that showed antidepressants ... and neck cancer patients is the focus of an ... one of the publications produced by the Journal of ... led by UNMCs William Lydiatt, M.D., and Bill Burke, ...
Cached Medicine News:Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:Gypsum Wallboard from CertainTeed's Moundsville, W. Va., Plant and Roofing Shingles among Building Materials Donated to St. Jude Dream Home(R) 2Health News:Mount Tabor Collaborates with Google Health 2Health News:U.S. Turns Spotlight on Medicine's Most Puzzling Cases 2Health News:JAMA publication features study on depression and head and neck cancer 2
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Open 14 mm blades with 10 mm lifting wings. Lightweight wire. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 14 mm blades with 6 mm lifting wings. Dull finish....
Medicine Products: